Evolus has signed an exclusive U.S. licensing agreement with IBSA for Profhilo, the Italian hybrid hyaluronic-acid injectable designed for skin quality and hydration rather than volumization. The deal carries no upfront payment, suggesting Evolus is betting on royalty-based returns over time. Profhilo operates on a different mechanism than traditional HA fillers—it's a low-viscosity, high-concentration HA product that spreads and integrates into the dermis, positioning it as a complement to neuromodulators and a competitor to products like Juvéderm Hydro and Restylane Vital.